Fuhe Biomedical and tech startup Graphen signed AI cooperation to sprint tumor immune precision

Posted by Global Bio on Dec 12, 2019

Alt Text Fuhe Biomedical and startup Graphen signed an AI cooperation on the 10th of this month to fully sprint tumor immune precision. Left: Jianmou Li, general manager of Fuhe Biomedical; right: Ching-Yung Lin, founder of Smart Technology, a US business plan. (Photo / Lin Jiaqing)

FullHope Biomedical, which specializes in immunotherapy, announced on the 10th this month that it has officially signed a cooperation with Graphen, inc., an AI network data analysis technology that Pride Intelligent Technology is proud of Combined with Fuhe Biomedical's immune function analysis, it is a step towards highly personalized precision medicine.

Jianmou Li, general manager of Fuhe Biomedicine, pointed out that providing a comprehensive and comprehensive assessment of immune capabilities in response to patients' needs for tumor immunological (IO) therapy has always been a key development direction of Fuhe Biomedical. Although the advent of target drugs in the past ten years has provided new hope for cancer patients in addition to radiotherapy and chemotherapy, in fact, the overall survival period has mostly been extended for no more than 6 months, and the success rate of target treatment will vary from person to person. It has been shown that in order to effectively treat cancer, the individual differences of patients must be better understood.

Therefore, to make IO therapy more perfect, it is bound to move towards more highly personalized precision medical development. In addition to the evaluation of the immune system, it is also necessary to establish a database of tumor tissue section images, blood tests, liquid biopsy and other three periods before, during, and after treatment, and to clarify the complex causality behind each patient's condition To help physicians find the most accurate treatment plan.

Jianmou Li said that becoming a partner with Graphen will not only speed up the analysis of the huge data of Fuhe Biomedical, but also enable Fuhe Biomedical to repeat through the AI computing network of Graphen. During the verification process, the core factor that is really important in tumor immunotherapy is gradually approached, "It is like picking pearls from the sea!"

Alt Text Group photo of the two teams of Fuhe Biomedical and Graphen. (This picture is provided by Fuhe Biomedical)

Dr. Ching-Yung Lin, the founder and CEO of Graphen, is an internationally renowned Taiwanese AI scientist. Prior to the establishment of Graphen, Ching-Yung Lin had worked at IBM for more than 17 years, developed more than 36 innovative patents including finance and medical treatment, and had considerable experience in innovative research and development. He said that he was very happy to use this cooperation to help Fuhe Biomedical to move closer to precision medicine in tumor immunotherapy.

Ching-Yung Lin pointed out that the strength of Graphen lies in networked association analysis. The knowledge map is established through AI, which makes the reasonability between complex factors higher. Tusmart Intelligent Technology has been engaged in the development of health care software a year and a half ago. Center, MSKCC) collaborated on cancer research.

"Although the" Methods for the Implementation or Use of Specific Medical Technical Inspection and Inspection Medical Devices "(Special Administrative Measures) have approved six cell therapies, the number of cases actually receiving treatment is still very small," Jianmou Li said. In the future, we also look forward to working with Graphen to provide patients with more accurate tumor immunotherapy services.

Source: original story in Chinese http://www.gbimonthly.com/2019/12/58808/